Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: A longitudinal study

Circulation: Cardiovascular Genetics

Volumn 2, Issue 6, 2009, Pages 621-628

  Rotger, Margalida ^a   Bayard, Cornelia ^a   Taffé, Patrick ^b   Martinez, Raquel ^a   Cavassini, Matthias ^c   Bernasconi, Enos ^d   Battegay, Manuel ^e   Hirschel, Bernard ^f   Furrer, Hansjakob ^g   Witteck, Andrea ^h   Weber, Rainer ^c   Ledergerber, Bruno ^c   Telenti, Amalio ^a   Tarr, Philip E ^e  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Swiss HIV Cohort Study Data Center   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h Infectious Diseases   (Switzerland)

Author keywords

Cardiovascular diseases; Genetics; Genome wide analysis; HIV infection; Hypercholesterolemia

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DYSLIPIDEMIA; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; FOLLOW UP; GENETICS; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 77449143922     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.874412     Document Type: Article

References (50)

1. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M. EpiDemiological eviDence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-e35.
2. DAD Study Group; Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunoDeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506-2512.
4. LeDergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R. Factors associated with the inciDence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111-119.
5. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Moller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunoDeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009;119:805-811.
6. Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis-Taillard C, De Valliere S, Hayoz D, Tarr PE; Swiss HIV Cohort Study. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46:761-767.
7. Grunfeld C, Kotler DP, HamaDeh R, Tierney A, Wang J, Pierson RN. HypertriglyceriDemia in the acquired immunoDeficiency syndrome. Am J Med. 1989;86:27-31.
8. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, EVans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
9. Fontas E, Van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, De Wit S, Lundgren JD, Pradier C, Reiss P; D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
10. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585-591. (Pubitemid 41224950)
11. Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; Swiss HIV Cohort Study. Contribution of 20 single nucleotiDe polymorphisms of 13 genes to dyslipiDemia associated with antiretroviral therapy. Pharmacogenet Genomics. 2007;17:755-764.
12. Fauvel J, Bonnet E, RuiDavets JB, Ferrieres J, Toffoletti A, Massip P, Chap H, Perret B. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceriDe/low HDL levels in treated HIV patients. AIDS. 2001;15:2397-2406.
13. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube MP, Tebas P, Reilly MP. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52.
14. Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, LeDergerber B, Telenti A. MoDeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorDers. J Infect Dis. 2005;191:1419-1426.
15. Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther. 2007;12: 999-1013.
16. Chang SY, Ko WS, Kao JT, Chang LY, Sun HY, Chen MY, Hsieh SM, Sheng WH, Chang SF, Liu WC, Wu CH, Hsu HJ, Kao CL, Lee CN, Hung CC, Chang SC. Association of single-nucleotiDe polymorphism 3 and c.553G+T of APOA5 with hypertriglyceriDemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hivinfected individuals in Taiwan. Clin Infect Dis. 2009;48:832-835.
17. Wellcome Trust Case Control Consortium. Genome-wiDe association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
18. Kathiresan S, MelanDer O, Guiducci C, Surti A, Burtt NP, RieDer MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-MelanDer M. Six new loci associated with blood low-Density lipoprotein cholesterol, high-Density lipoprotein cholesterol or triglyceriDes in humans. Nat Genet. 2008;40:189-197.
19. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the Development of type 2 diabetes. N Engl J Med. 2008; 359:2220-2232.
20. Meigs JB, ShraDer P, SulliVan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB Sr, Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-2219.
21. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. GenomewiDe association analysis of coronary artery disease. N Engl J Med. 2007;357:443-453. (Pubitemid 47204873)
22. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, PapaDakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M, Luben R, Sims M, Hadley D, McArdle W, Barter P, Kesaniemi YA, Mahley RW, McPherson R, Grundy SM, Bingham SA, Khaw KT, Loos RJ, Waeber G, Barroso I, Strachan DP, Deloukas P, VollenweiDer P, Wareham NJ, Mooser V. LDL-cholesterol concentrations: a genome-wiDe association study. Lancet. 2008;371:483-491.
23. Saxena R, Voight BF, Lyssenko V, Burtt NP, De Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson BK, Isomaa B, Lettre G, Lindblad U, Lyon HN, MelanDer O, Newton-Cheh C, Nilsson P, Orho-MelanDer M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, BroDeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S. Genome-wiDe association analysis iDentifies loci for type 2 diabetes and triglyceriDe levels. Science. 2007;316:1331-1336.
24. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, vey-Smith G, Shuldiner AR, Collins R, Bergman RN, UDa M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly iDentified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
25. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, De Bakker PI, Abecasis GR, Almgren P, AnDersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, HerDer C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, PeDersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D. Meta-analysis of genome-wiDe association Data and large-scale replication iDentifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40:638-645.
26. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, PeDersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, RuDan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, De Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, SilanDer K, Isaacs A, Sijbrands EJ, UitterlinDen AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring A, Wichmann HE, Smit JH, McCarthy MI, Van Duijn CM, Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47-55.
27. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, UDa M, Yang Q, Lunetta KL, Dupuis J, De Bakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, MelanDer O, Salomaa V, Peltonen L, Orho-MelanDer M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci contribute to polygenic dyslipiDemia. Nat Genet. 2009;41:56-65.
28. Manolio TA. Cohort studies and the genetics of complex disease. Nat Genet. 2009;41:5-6.
29. Kathiresan S, MelanDer O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-MelanDer M. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240-1249.
30. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, Jones CG, Zaitlen NA, Varilo T, Kaakinen M, Sovio U, Ruokonen A, Laitinen J, Jakkula E, Coin L, Hoggart C, Collins A, Turunen H, Gabriel S, Elliot P, McCarthy MI, Daly MJ, Jarvelin MR, Freimer NB, Peltonen L. Genome-wiDe association analysis of metabolic traits in a birth cohort from a founDer population. Nat Genet. 2009;41:35-46.
31. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
32. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:153-162.
33. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, AranDa M, Cruceta A, De Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunoDeficiency virus infection. N Engl J Med. 2003;349:1036-1046.
34. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Atherogenic dyslipiDemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
35. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipiDaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
36. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, De Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298:1300-1311.
37. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceriDe levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33:447-454.
38. Kuivenhoven JA, Jukema JW, ZwinDerman AH, De Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338:86-93.
39. Lee KW, Ayyobi AF, Frohlich JJ, Hill JS. APOA5 gene polymorphism modulates levels of triglyceriDe, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis. 2004;176:165-172.
40. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglyceriDes in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
41. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two inDepenDent apolipoprotein A5 haplotypes influence human plasma triglyceriDe levels. Hum Mol Genet. 2002;11:3031-3038.
42. Murtaugh P. Methods of variable selection in regression moDeling. Comm Stat Simulat Comput. 1998;27:711-734.
43. Zucchini W. An introduction to moDel selection. J Math Psychol. 2000; 44:41-61.
44. Schemper M. Predictive accuracy and explained variation. Stat Med. 2003;22:2299-2308.
45. Xu R. Measuring explained variation in linear mixed effects moDels. Stat Med. 2003;22:3527-3541.
46. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
47. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1066-1074.
48. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
49. Tiret L, Tregouet DA, Cambien F. Cholesterol gene polymorphisms and cardiovascular events. N Engl J Med. 2008;359:92-93.
50. Vergeer M, El-Harchaoui K, Stroes ES. Cholesterol gene polymorphisms and cardiovascular events. N Engl J Med. 2008;359:92.